|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administration_schedule
|
0, 28, and 56 days
|
|
gptkbp:age_approval
|
12 years and older
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
gptkb:India
Phase 3
approximately 28,000
|
|
gptkbp:clinical_trial_results_published
|
gptkb:Lancet
|
|
gptkbp:country_of_origin
|
gptkb:India
|
|
gptkbp:delivery_system
|
needle-free injector
|
|
gptkbp:developed_by
|
gptkb:Zydus_Cadila
|
|
gptkbp:dosage_form
|
gptkb:3
not required for primary series
|
|
gptkbp:effective_date
|
August 2021
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zy Co V-D
|
|
gptkbp:innovation
|
first DNA vaccine approved for human use
|
|
gptkbp:is_effective_against
|
66.6% in preventing symptomatic COVID-19
|
|
gptkbp:is_vulnerable_to
|
gptkb:government
affordable
ongoing studies
recombinant DNA
government and private sector
strong immune response
preventive vaccine
campaigns conducted
collaborations with health organizations
effective against variants
adverse event reporting system
high effectiveness against severe disease
reduces hospitalization rates
3 doses required
multicenter trials conducted.
|
|
gptkbp:manufacturer
|
gptkb:Zydus_Cadila_Healthcare_Ltd.
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:market_position
|
available
|
|
gptkbp:regulatory_compliance
|
DCGI approval
|
|
gptkbp:route_of_administration
|
intradermal
|
|
gptkbp:safety_features
|
well-tolerated
|
|
gptkbp:side_effect
|
mild to moderate reactions
|
|
gptkbp:supply_chain
|
cold chain required
|
|
gptkbp:target_audience
|
adolescents and adults
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
DNA vaccine
|
|
gptkbp:uses_technology
|
plasmid DNA technology
|
|
gptkbp:vaccine_approval_authority
|
gptkb:Indian_government
|
|
gptkbp:vaccine_distribution_method
|
gptkb:health_services
|
|
gptkbp:whoemergency_use_listing
|
gptkb:Yes
|
|
gptkbp:bfsParent
|
gptkb:GSK
|
|
gptkbp:bfsLayer
|
4
|